Jaffetilchin Investment Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.69M | Buy |
16,974
+6,817
| +67% | +$1.51M | 0.22% | 83 |
|
|
2025
Q4 | $2.32M | Buy |
10,157
+1,102
| +12% | +$251K | 0.14% | 109 |
|
|
2025
Q3 | $2.1M | Sell |
9,055
-349
| -4% | -$71.1K | 0.13% | 114 |
|
|
2025
Q2 | $1.75M | Sell |
9,404
-495
| -5% | -$92K | 0.11% | 122 |
|
|
2025
Q1 | $2.07M | Buy |
9,899
+418
| +4% | +$81.3K | 0.15% | 111 |
|
|
2024
Q4 | $1.68M | Buy |
9,481
+543
| +6% | +$99.8K | 0.12% | 115 |
|
|
2024
Q3 | $1.77M | Buy |
8,938
+775
| +9% | +$145K | 0.13% | 99 |
|
|
2024
Q2 | $1.4M | Sell |
8,163
-2,388
| -23% | -$396K | 0.12% | 105 |
|
|
2024
Q1 | $1.92M | Sell |
10,551
-3,269
| -24% | -$563K | 0.17% | 88 |
|
|
2023
Q4 | $2.14M | Buy |
13,820
+494
| +4% | +$72K | 0.21% | 80 |
|
|
2023
Q3 | $1.99M | Buy |
13,326
+2,471
| +23% | +$363K | 0.22% | 74 |
|
|
2023
Q2 | $1.46M | Sell |
10,855
-530
| -5% | -$77.7K | 0.15% | 94 |
|
|
2023
Q1 | $1.81M | Buy |
11,385
+3,651
| +47% | +$558K | 0.21% | 88 |
|
|
2022
Q4 | $1.25M | Buy |
7,734
+1,984
| +35% | +$304K | 0.15% | 111 |
|
|
2022
Q3 | $772K | Sell |
5,750
-3,130
| -35% | -$449K | 0.1% | 130 |
|
|
2022
Q2 | $1.36M | Buy |
8,880
+242
| +3% | +$37K | 0.16% | 95 |
|
|
2022
Q1 | $1.33M | Sell |
8,638
-786
| -8% | -$114K | 0.16% | 92 |
|
|
2021
Q4 | $1.28M | Sell |
9,424
-624
| -6% | -$73.7K | 0.12% | 119 |
|
|
2021
Q3 | $1.08M | Sell |
10,048
-141
| -1% | -$16.1K | 0.12% | 125 |
|
|
2021
Q2 | $1.15M | Buy |
10,189
+1,046
| +11% | +$118K | 0.08% | 163 |
|
|
2021
Q1 | $989K | Buy |
9,143
+3,448
| +61% | +$369K | 0.12% | 131 |
|
|
2020
Q4 | $610K | Buy |
5,695
+2,479
| +77% | +$238K | 0.09% | 145 |
|
|
2020
Q3 | $282K | Sell |
3,216
-3,728
| -54% | -$351K | 0.05% | 193 |
|
|
2020
Q2 | $682K | Buy |
+6,944
| New | +$611K | 0.15% | 88 |
|
|
2020
Q1 | – | Sell |
-2,455
| Closed | -$217K | – | 156 |
|
|
2019
Q4 | $217K | Buy |
+2,455
| New | +$204K | 0.05% | 217 |
|
|
2018
Q3 | – | Sell |
-12,131
| Closed | -$1.12M | – | 300 |
|
|
2018
Q2 | $1.12M | Buy |
12,131
+7,431
| +158% | +$726K | 0.25% | 73 |
|
|
2018
Q1 | $445K | Sell |
4,700
-11,966
| -72% | -$1.31M | 0.1% | 177 |
|
|
2017
Q4 | $1.61M | Buy |
16,666
+3,380
| +25% | +$319K | 0.54% | 36 |
|
|
2017
Q3 | $1.18M | Buy |
13,286
+1,751
| +15% | +$133K | 0.28% | 61 |
|
|
2017
Q2 | $836K | Buy |
11,535
+810
| +8% | +$54.5K | 0.28% | 66 |
|
|
2017
Q1 | $699K | Buy |
10,725
+87
| +0.8% | +$5.47K | 0.18% | 93 |
|
|
2016
Q4 | $666K | Sell |
10,638
-4,182
| -28% | -$255K | 0.2% | 83 |
|
|
2016
Q3 | $935K | Buy |
14,820
+1,478
| +11% | +$95.7K | 0.3% | 48 |
|
|
2016
Q2 | $826K | Buy |
+13,342
| New | +$813K | 0.25% | 55 |
|
|
2016
Q1 | – | Sell |
-3,620
| Closed | -$214K | – | 184 |
|
|
2015
Q4 | $214K | Buy |
+3,620
| New | +$209K | 0.07% | 173 |
|
|
2015
Q3 | – | Sell |
-3,620
| Closed | -$243K | – | 176 |
|
|
2015
Q2 | $243K | Sell |
3,620
-16
| -0.4% | -$1.04K | 0.07% | 167 |
|
|
2015
Q1 | $213K | Buy |
+3,636
| New | +$220K | 0.06% | 204 |
|
|
2014
Q4 | – | Sell |
-11,612
| Closed | -$671K | – | 182 |
|
|
2014
Q3 | $671K | Sell |
11,612
-1,445
| -11% | -$80.2K | 0.25% | 61 |
|
|
2014
Q2 | $737K | Buy |
+13,057
| New | +$685K | 0.26% | 67 |
|
|
2014
Q1 | – | Sell |
-19,210
| Closed | -$1.01M | – | 184 |
|
|
2013
Q4 | $1.01M | Buy |
+19,210
| New | +$944K | 0.5% | 43 |
|
Other funds holding ABBV
Jaffetilchin Investment Partners's ABBV Position: Q1 2026 in Review
Jaffetilchin Investment Partners increased its AbbVie (ABBV) stake by 67% in Q1 2026, buying an estimated $1.51M and bringing the position to 16,974 shares worth $3.69M. The position accounts for 0.22% of the portfolio, ranked #83.
Jaffetilchin Investment Partners first reported a position in ABBV in Q4 2013 and has held it in 40 quarters since. 4,098 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Jaffetilchin Investment Partners held 16,974 shares of AbbVie worth $3.69M as of Q1 2026.
- Jaffetilchin Investment Partners bought 6,817 AbbVie shares in Q1 2026, an estimated $1.51M.
- AbbVie made up 0.22% of Jaffetilchin Investment Partners's portfolio in Q1 2026, its #83 holding.
- Jaffetilchin Investment Partners first reported a position in AbbVie in Q4 2013 and has held it in 40 quarters since.
- 4,098 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Jaffetilchin Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.